Vita 34 AG
ISIN: DE000A0BL849
WKN: A0BL84
01 August 2024 12:39PM

EQS-News: Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG

Vita 34 AG · ISIN: DE000A0BL849 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1959319

EQS-News: Vita 34 AG / Key word(s): Personnel
Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG

01.08.2024 / 12:39 CET/CEST
The issuer is solely responsible for the content of this announcement.


Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG

  • Assumption of the position as per 1 August 2024
  • Management Board completed again after a few months of vacancy

Leipzig, 1 August 2024 – The Supervisory Board of Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third largest in the world, has appointed Mr. Thomas Pfaadt (51) as new Chief Financial Officer effective today.

Thomas Pfaadt has more than 20 years of professional experience in various areas of finance. After studying business administration at Goethe University Frankfurt am Main, he held positions of responsibility in the areas of M&A and Corporate Finance at PricewaterhouseCoopers and DZ Bank. He then took on management roles in these areas at two leading German companies in the healthcare industry, before taking on the position of CFO and Managing Director at C-Lecta GmbH, a global biotechnology company for enzyme products, in 2018.

"We are delighted to have won Thomas Pfaadt, a CFO with a wealth of experience, for our company," says Jakub Baran, CEO of Vita 34 AG. "With his appointment, the Management Board is now complete again with three members after a few months of vacancy."

As a member of the Management Board of Vita 34 AG, Thomas Pfaadt will be mainly responsible for the areas of Finance, Controlling, Accounting, Procurement and Administration. His appointment is initially for a term of three years.

Contact:
Vita 34 AG
Investor Relations
Phone: +49 (0341) 48792 – 40
E-mail: ir@vita34.de

Company Profile

Vita 34 was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. Due to the expansion of the business model following the merger with PBKM, the company intends to invest in the areas of Cell & Gene therapies and CDMO. The body's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with around one million units of stored biological material at Vita 34.



01.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1959319

 
End of News EQS News Service

1959319  01.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1959319&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 20,41 19,93 20,07 28,42 68,94 77,06 86,00
EBITDA1,2 4,72 5,43 5,34 0,81 -3,56 5,57 7,40
EBITDA-Margin3 23,13 27,25 26,61 2,85 -5,16 7,23 8,61
EBIT1,4 2,63 2,45 2,38 -3,07 -27,28 -3,12 -1,20
EBIT-Margin5 12,89 12,29 11,86 -10,80 -39,57 -4,05 -1,40
Net Profit (Loss)1 0,83 0,72 1,50 -3,93 -27,38 -2,03 -2,90
Net-Margin6 4,07 3,61 7,47 -13,83 -39,72 -2,63 -3,37
Cashflow1,7 4,60 6,32 3,98 2,73 -4,49 9,15 0,00
Earnings per share8 0,20 0,18 0,37 -0,63 -1,71 -0,12 -0,16
Dividend per share8 0,16 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: PricewaterhouseCoopers

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Vita 34
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A0BL84 DE000A0BL849 AG 72,68 Mio € 27.03.2007 Halten 9F3J899W+W5
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
0,00 27,07 0,00 -35,83 3,19 7,94 0,94
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2024 31.05.2024 30.08.2024 22.11.2024 30.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+2,49%
4,12 €
ATH 18,82 €
-4,19% -8,57% -21,37% -19,22% -72,53%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL